We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Draft Guidance on Labeling for NDAs, BLAs and Combo Products
FDA Issues Draft Guidance on Labeling for NDAs, BLAs and Combo Products
The FDA released draft guidance on Monday on the content and formatting of Instructions for Use (IFU) for prescription drugs, biologics, and drug- or biologic-device combinations.